

Identification of Taxa and Functional Pathway Information of *Mycobacterium tuberculosis* Microbiome and High Throughput Simulation Studies with Mycobacteriophage

Divya Verma^{1,2(IM)}, I. A. Shylesh Murthy², and Preenon Bagchi^{1,2,3}

¹ Padmashree Institute of Management and Sciences, Bengaluru, India prithish.bagchi@gmail.com

² Vasishth Academy of Advanced Studies and Research, Sarvasumana Association, Bengaluru,

India

³ MGM Institute of Biosciences and Technology, Aurangabad, India

Abstract. Tuberculosis caused by bacteria Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine and brain. Mycobacterium tuberculosis in lungs microbiome can be studied by metamorphic mechanization specifically metatransriptomics sequencing. These sequencing allow us to investigate the DNA content, RNA content, bacterial taxa and functional pathways. Further by taking antibiotic resistant protein from bacteria, we establish that bacteriophage lysine BD29 (PDB-3HC7) can lyse mycolylarabinogalactan bonds and releases free mycolic acid. It do not show action on peptidoglycan bond. Based on information a full surface docking was performed. To verify assignment, a molecular dynamics simulations was performed to assess the stability of the docked substrates. MD simulation suggested hydrolytic activity of amino acids residues on Mycobacterium tuberculosis. Docking and simulation of bacteriophage D29 lysin B gene protein 12 with multiple antibiotic resistant proteins which takes part in transcription process in bacteria. Here, mycobacteriophage D29 showed a potent inhibition on action of antibiotic resistant protein during transcription process. This action resulted by modification or deactivation of amino acid residues.

Keywords: *Mycobacterium tuberculosis* · Microbiome · Mycobacteriophage lysine D29 · next generation sequencing · global alignment · Operational taxonomic unit · Taxonomy · modeling · docking and molecular dynamics

1 Introduction

Mycobacterium tuberculosis is potential reason for pulmonary complications include hemoptysis, pneomothorax, bronchiectasis, extensive pulmonary destruction and there is substantial interest in establishing the foremost effective treatment. It is the most typically reported as super bugs among the persons aged 25–65 years. Tuberculosis characterized by extracellular bacilli are ingested by macrophages and presented to other

white blood cells. This triggers the immune response in which white blood cells kill or encapsulate most of the bacilli, leading to the formation of granuloma. Tuberculosis has been associated with serious health issues which includes extrapulmonary TB, miliary TB and central nervous system TB (which surrounds the brain or spinal cord). Symptoms include a cough that last 3 weeks or longer, pain in chest, coughing up blood or sputum, weight loss, fever, sweating at night. *Mycobacterium tuberculosis* strain responsible for a large multidrug resistant TB. The outbreak started in the mid 2000 and in earlier 1990s.TB is still one leading causes of mortality worldwide. Factors contributing to the situation are HIV/AIDS pandemic [1–4].

Several genes and chromosomal regions have been found to be associated with mycobacterium in various linkages and analyses, case control studies, genome wide association studies, mapping studies. Studies shown the association of genetic variations with pathogenesis and drug resistance. Pathogenic variants in genes of high and moderate penetrance-Erm 37, TlyA, Rpob, Eis, InhA, KasB and MarA which confers resistant towards various types of antibiotics [1–4].

Due to arrival of Next generation sequencing the detection of these pathogenic variants genes became possible. Next generation sequencing technology initially was concerned with studying genomes that were tractable from the standpoint size and repetitive content and with characterization of multiple genes associated with the disease. The technology used to determine the order of nucleotides or targeted regions of DNA or RNA. Here raw data generation is no longer a rate limiting factor in genome scale studies. Galaxy an open source for NGS data analysis. The pipeline worned here is metatranscriptomics analysis which allows us to understand how the microbiome retaliate to the host by studying effective analysis of genes expressed.Further using the tools of computer aided drug design, we have tried to establish the novel polypeptides lysine B D29 gene 12 from Mycobacteriophage [1–4].

Metatranscriptomics analysis

Next-generation sequencing (NGS) is an advanced version of non-Sanger-based sequencing technology that offers ultra-high throughput, scalability, and speed. Galaxy is an open source, web-based platform for next generation computational biomedical research [5]. Metatranscriptomics analysis enables understanding of how the microbiome responds to the environment by studying the functional analysis of genes expressed by the microbiome [6]. The genes from the Metagenomic analysis were transcribed from functional data, active metabolic pathways can be identified in our selected microbiome community [7].

Computer aided Drug design

Drug design is the whole process of taking a newly discovered compound or drug molecule. Structure based drug designing technique is used here to build, display, simulate and analyze the molecular structure. Here we have used SWISS-MODEL tool [8] for modelling the proteins (gene receptors) responsible to bind antibiotic resistant protein.Gene receptors are as follows CR3, Dectin 1, IRAK4 and CXCL8. Selected models from homology modelling output are docked with selected antibiotic resistant proteins from *Mycobacterium tuberculosis*. Selection of antibiotic resistant protein was done based on it's appropriate target sites for specific gene receptors. Molecular docking

was done using Patchdock tool [9, 10] and best interacting antibiotic resistant bacterial proteins with the gene receptors was selected by identifying simulation prototype. SWISS-MODEL tool have also been used for modeling the bacterial proteins (antibiotic resistant protein) responsible to bind Mycobacteriophage Lysin B D29. Bacterial proteins are as follows InhA, KasB, Eis, WhiB7, Rpob, Erm37, TlyA, and Mar A. Selected model from homology modelling output are docked with selected Mycobacteriophage lysine B D29.Molecular docking was performed using patch dock tool and best interacting Mycobacteriophage lysine B D29 with the antibiotic resistant bacterial proteins was identified by Molecular dynamics simulation.

Mycolylarabinogalactan recognition by mycobacteriophage protein is an important part of biological system. However there is only one specific protein for recognition of mycolylarabinogalactan i.e., Mycobacteriophage lysine B gp12.Substrate recognition for enzyme is varied. The sites containing aromatic residues can be classified into 3 types depending on arrangement-parallel arrangement/planar arrangement, juxtaposed arrangement, sandwich type arrangement. The interaction arrangement limits the type of substrates for catalytic mechanism. Bacteriophage receptors for bacteria divided into 3 major groups depending on the nature of ligand. The first and the most predominant group recognize mycolylarabinogalactan in the cell wall and second group recognizes proteins and the third group recognizes mixed receptors (proteins or carbohydrate receptor).

It is shown that the Mycobacteriophage D29 lysin B gp 12 protein have hydrolytic activity towards mycolylarabinogalactan. The protein activity is unusual and there has been interest in elucidating potential mechanism of catalytic activity. Therefore insilico analysis of protein was performed to identify putative binding sites and catalytic residues. The docking was performed to analysed putative binding sites and catalytic residues and is verified by molecular dynamics simulation. The results were compared with other bacterial proteins involved in antibiotic resistant. Analysis of virtual mutants also suggested strong preference of enzyme for catalytic efficiency at the cost of stability and putative affinity.

MD Simulation by Vienna ptm 2.0. MD simulation a whole process which undergo conformational changes of both ligand and proteins. Conformation is one of the factor taken into account on computer docking simulation. However side chain motion are generally coupled to back bone motion and the latter can be significant. The best way to explore relevant backbone and sidechain flexibility by Molecular dynamics simulation.MD simulation depicts distance dependent dielectric model, in which electrostatic screening expressed. It is conducted for the complexation of substrate with the inhibitor, complexation of protein domain with doubly phosphorylated peptide ligand.Here electrostatic interaction are important driving force for docking and protein undergo modest changes in conformation upon binding.

2 Materials and Methods

Mycobacterium tuberculosis fastq sequences SRR14690790.1.1 and SRR14690790.1.2 were retrieved from SRA database.

Sequence's quality was checked using FASTQC [11]. MultiQC [12] was done to aggregate results from FASTQC analyses into a single report. Sequences were trimmed using cutadapt.

FASTQC followed by MultiQC was re-run using the results of cutadapt.

Next, using SortMeRNA tool [13] any reads identified as rRNA in dataset was removed.

Next, using FASTQ INTERLACER tool [14] paired end FASTQ reads from two separate files were joined.

MetaPhlAn tool [15] was used for profiling the composition of microbial communities (Bacteria, Archaea and Eukaryotes) from our microbiota.

Krona tool [16] was used to visualize the results of a metagenomic profiling as a zoomable pie chart and GraPhlAn tool [17] for visualizing high-quality circular representations of taxonomic and phylogenetic trees.

Further, HUMAnN [18] pipeline was used for efficiently and accurately profiling the presence/absence and abundance of microbial pathways in our microbiota.

Next, using the genes present in our microbiota, their 3d structure was modeled using SWISS-MODEL [8].

Mycobacteriophage lysin B D29 were downloaded from RCSB.

Further, docking was performed using patchdock [9, 10].

Vienna PTM using Molecular dynamics simulation. Here desired proteins are modified with one or supported Post translational modifications and obtain force field parameters(GROMOS, 45A3, 54A8) with the help of input files MD simulations were performed using GROMACS package.

3 Results and Discussion

Metagenome analysis

Metagenome, having accession number SRR14690790, for *Mycobacterium tuberculosis* was downloaded from SRA database.

As, per **Per base sequence quality** results (Fig. 1) of FASTQC and MultiQC, the sequence quality is not good hence we go ahead with trimming the sequence.

CUTADAPT tool [27] is used for trimming. It finds and removes adapter sequences, primers, poly-A tails, and other types of unwanted sequence from our data. It searches for the adapter in all reads and removes it when it finds it. Further, sequence quality of the cutadapt output is checked using FASTQC and MultiQC and it is found within the range.

SortMeRNA tool removes any reads identified as rRNA from our dataset. Fastq Interlace tool joins paired end FASTQ reads from two separate files. Taxonomic profiling [28] was done using MetaPhlAn tool (Table 1). The output is visualized using Krona and Graphlan (Fig. 2, Fig. 3).

After generation of taxonomy, we move to functional information of our microbiome. Functional information of the above microbiome community [28] was done using HUMAnN pipeline.



Fig. 1. MultiQC result before Trimming-



Fig. 2. Generation, personalization and annotation of tree: Tree in PhyloXML




Fig. 3. Visualization of Taxonomic profile in Krona and GraPhlAn

Next, from the gene family information, we obtain the functional information of our microbiome using Superfamily server. The Functional information of 1st five families from Normalized gene families as detected by Superfamily (HMM library and genome assignments server) is given in Table 2 and 3.

# Gene Family	humann_Abundance-RELAB
UNMAPPED	0.999872
UniRef90_X8FHU5	0.000116922
UniRef90_X8FHU5lunclassified	0.000116922
UniRef90_Z9JRB3	1.08765e-05
UniRef90_Z9JRB3lunclassified	1.08765e-05

Table 1. Normalized gene families

Table 2. Superfamily information

Domain ass	ignment for X8FH	U5 from Uniprot 2018_03 genome
Domain archited	ture	
	1	
eLDH-11ke		•
_		
 Other domai 	ns with this domain archited n architectures with similar ogenetic distribution for this	genomic distribution
Domain assignment detai	k	Proteini sequence
(show help) Streng hits		Erand SH45
sengina		Siguro Til
Sequence: <u>XEFHUS</u>		eph
Domain Number 1 Region: 2		Dimmet (*) 1994/51 (1994), 500 L) (570 educile address and depress (200 00000) (598, 5940722.1) (1994) makes onderne Referenz anderne (hr. 1995), 00-Micobachrism (known at Hanes (hr. 1995), 000 Orthopachrism.
Classification Level Classifica		Searco Contenting and a search of the content of th
Superfamily ALDH-like		PETER AND DATE TO A DATE OF A DATE O
Family ALDH-Ike		101096203390012900081603000000 00000200002000000000000000000
Further Details: Finis Detail	Algenets Enume Assignments Exercise Combinations	Dariel Ba
		240 C
		Identical Institution Institution
UniRef90_2	K8FHU5,	
Human abu	ndances-0.0001169	922

Table 3. Superfamily information

Domain architectu	re		
1	3		2
Other proteins Other domain a	 Succinate dehydrogenase/# with this domain archito inchitectures with simila enetic distribution for the 	ecture ir genomic (listribution
imain assignment details on hiti mg hiti		Pratizie sequence	
quence: 20002 ensin Number 1 Region: 2-202,301-420 selfcarlos Lossi Classification	Y-value	tona 2001	
performily DICLIGIATIS banders durante why Cuscinates delty choreeness framanates	3.45e-72 reducters flevorrober Miterminal domain 0.00000001		
reber Details: Entricited Streets Entries			2001, Milli Gone-Bhotopee Barnoli alar (30,00009) Mee Holdto Is priore, Newsonio of 2000, 2014/01-668 (acres physicana, 01499), p 80447
essilication (card/Canadication perfamily Decourse development for an de- min development development for an de- ather Details: (arth/detail) (bernen) (once to ge	Produce Productions Francescones Commence Commence Productions Francescones Commence Commence Income Commence Examples	Reverse Revers	INNER JOHN CYTOPIOCK WEI TOPINOCUS STATUS INTERVOLUE WEI C.
man Tander 3 Region 200 317 swifterfor Loof Classification formation in the standard statements who success dividuos and the statements	Inductoria flavoricitati, ordevici domani, 1.644-40 Inductoria flavoricitati, ordevici domani, 0.0001149	K-02.49 (73)895	nerrozarotekorekorot
evilication Level Classification writerity Success dehydroseneos fair ante-	Induction Recordsen, orbitol domain (1.646-40) Induction Recordsen, orbitol domain (0.0001149)	Contral Dontal Detainte Detain	nekkeantikonekken

227

Relationships were determined

By using this factor we selected the specific bacteriophage (Mycobacteriophage lysine B D29 gp12) (Table 4). It is determined by global alignment tool from NCBI (Fig. 4).

Global alignment result

Needleman-Wunsch algorithm. Source-https://blast.ncbi.nlm.nih.gov.

SL.NO	ORGANISMS	ACCESSION NO
1.	Mycobacteriophage D29 DNA coat protein	X70353.1
2.	Mycobacterium tuberculosis H37Rv	KY702779.1
See Fig. 4		

 Table 4.
 NCBI accession number of organisms




Fig. 4. Dot-plot

Sl. No	Gene Receptors	Number NCBI Accession	Homologous Template
1.	CR3	QRN45544.1	3K6SB
2	Dectin 1	AAH71746.1	1MPUA
3	IRAK4	NP_001338274.1	5UIUA
4	CXCL8	NP_001341769.1	6N2UA

Table 5. Genes with their NCBI Accession number

3.1 Structure Based Drug Designing of Mycobacterium Tuberculosis

Since, Tuberculosis is bacterial disease; we further go ahead towards designing novel drug for the disease. From the MetaPhlAn: Bowtie2 output we get the gene ids. Corresponding gene receptors (macromolecules) are taken from NCBI for our work (Table 5).

Abbreviations of genes

- 1. CR3 Complementary Receptor
- 2. CLEC7A C-type lectin domain family 7, member A
- 3. CXCL8 C-X-C Motif chemokine ligand 8
- 4. IRAK4 Interleukin 1 Receptor Associated kinase 4

Homology modeling

Homology modeling of the above receptors are done using SWISS-MODEL server. The receptor model and corresponding ramachandran plot results are given in Fig. 5. Template used for modeling is given in Table 6.

Abbreviations of proteins

- 1. Eis Enhanced intracellular survival
- 2. Erm37 Expression resistant macrolide
- 3. InhA Inhibin alpha
- 4. KasB Beta keto acyl carrier protein
- 5. Mar A Multiple antibiotic Resistant
- 6. Rpob Rifampin resistant gene (Beta subunit of bacterial RNA polymerase)
- 7. Tly A Cytidine methyl transferase A
- 8. WhiB7 Probable transcription regulator

Homology modeling

Homology modeling of the above receptors (micromolecules) are done using SWISS-MODEL server. The receptor model and corresponding ramachandran plot results are given in Fig. 6. Template used for modeling is given in Table 6.

Sl. No.	Name of receptor	Modelled structure	Ramachandran plot of the modeled structure
1	CR3	and the	
2.	DECTIN	A A A A A A A A A A A A A A A A A A A	
3.	CXCL8	A CAR	
4.	IRAK4		

Fig. 5. Swiss-model generated receptor models with their ramachandran plot

Table 6. Proteins with their NCBI Accession number-	Table 6.	Proteins w	ith their NCI	3I Accession	number-
---	----------	------------	---------------	--------------	---------

SL.NO	PROTEINS	ACCESSION NUMBER	HOMOLOGOUS TEMPLATE	
1.	Eis	AVV29810.1	5EBV.1.F	
2.	Erm37	KBG11004.1	6NVM.1.A	
3.	Inh A	AVV29586.1	2PR.2.A	
4.	kasB	CCE37716.1	2GP.6.A	
5.	Mar A	OMH59859.1	3W6V.1.A	
6.	Rpob	AEJ88322.1	6VW.0.1.C	
7.	TlyA	CCP44459.1	5KS.2.1.A	
8.	WhiB7	AJF05229.1	7KIM.1.K	




Fig. 6. Swiss-model generated receptor models with their ramachandran plot

Bacteriophage exhibit catalytic mechanism on binding with various proteins or carbohydrates motif. This study of phage-host interaction can inform small molecule drug discovery by revealing new drug targets and pinpointing their weakness. Mycobacteriophage lysine B D29 can hydolysed the mycolylarabinogalactan bonds and inactivates antibiotic resistant proteins (Table 7). The potential activity of Mycobacteriophage lysine B D29 against antibiotic resistant protein of *Mycobacterium tuberculosis* is studied here.

SL.NO	TEMPLATE.NO	PROTEINS	LIGANDS	DOCKING SCORE Kcal/mol	RMSD Value Angstrom
1.	2PR2.1.A	Inh A	Phage lysine B D29	-16652	4
2.	2GP6.1.A	Kas B	Phage lysine B D29	-16012	4
3.	5EBV.1.F	Eis	Phage lysine B D29	-19224	4
4.	7KIM.1.K	WhiB7	Phage lysine B D29	-13710	4
5.	6VW0.1.C	Rpob	Phage lysine B D29	-18264	4
6.	6NVM.1.A	Erm37	Phage lysin B D29	-13614	4
7.	5KS2.1.A	TlyA	Phage lysine B D29	-13792	4
8.	3W6V.1.A	Mar A	Phage lysine B D29	-12638	4

 Table 7. Docking scores and RMSD value of Mycobacteriophage B D29 lysin with bacterial proteins

Table 8. Docking scores and RMSD value of Human receptors with bacterial proteins.

SL. NO	RECEPTOS	LIGAND- 1	LIGAND- 2	DS-1 Kcal/mol	DS-2 Kcal/mol	RMSD value angst-rom
1.	CR3	Eis	InhA	-14726	-14260	4
2.	DECTIN	WhiB7	Rpob	-12610	-17644	4
3.	IRAK4	KasB	Erm37	-16198	-15514	4
4.	CXCL8	TlyA	MarA	-14418	-15096	4

SL	Protein name	Mode-1	Residue-s	Residue-s	Charge-s
.N 0			(chainA)	(chainA)	
2.	Erm37-Expression resistant macrolide docked with Mycobacteriophage D29 lysin B gp12		1 14 24 35 38 45 53 55 59 84 91 106	Asp Ser Val Pro Gly Ala Pro Asn Val Ser Phe	0.129 -0.31 0.31 0.45 -0.31 0.45 -0.31 0.29 0.31 -0.31
3.	InhA-Inhibin alpha docked with Mycobacteriophage D29 lysin B gp12		1 8 26 35 40 53 71 79 87 89 95 101	Gly Leu Asp Gly Lys Arg Ile Leu Leu Val Ser Ser	0.129 -0.31 -0.31 -0.31 -0.31 -0.31 -0.31 -0.31 -0.31 -0.45 0 -0.45 0.31
4.	KasB-beta keto acyl carrier protein docked with Mycobacteriophage D29 lysin B gp12(Chain C)		1 9 27 37 47 53 75 85 91 97 105 113	Gly Leu Asp Gly Lys Arg Ile Leu Val Ser Gly Ile	0.129 0.31 0.129 -0.31 0 0 0 -0.31 0.31 0
5.	MarA-Multiple antibiotic resistant protein docked with Mycobacteriophage D29 lysin B gp12		1 13 22 30 46 60 77 86 93 98 99 99 100	Met Ser Pro Arg His Phe Thr Arg Arg Arg Arg Phe	-0.15 -0.31 0 0.31 0.31 0.31 0.31 0.34 0.24 0.35 0.31

Table 9. MD simulation results

(continued)

6.	Rpob-Rifampin resistant	Acres.	1	Gln	0.129
	protein docked with		15	Thr	-0.31
	Mycobacteriophage D29		25	Pro	0
	lysin B gp12		32	Arg	0.31
		A. C.	50	Gln	-0.31
			64	Arg	-0.31
		532	80	Leu	0
			89	Pro	0
		1 × 34	94	Val	0.31
		· · · ·	104	Leu	0
			110	Pro	0
7.	TlyA-Cytidine methyl		1	Arg	0.129
	transferase A docked		20	Ala	-0.31
	with Mycobacteriophage	man	28	Trp	0
	D29 Lysin B gp12		42	Trp	0.14
		A States	48	Val	0.31
			55	Ser	-0.31
		10 A	65	Arg	-0.31
			81	Gly	-0.31
			90	Ala	-0.45
			108	Lys	0
			122	Leu	-0.31
8.	WhiB7-Transcription		1	Gln	0.129
	regulator docked with	have	15	Thr	-0.31
	Mycobacteriophage D29	and second as in	24	Pro	0
	lysin B gp12		32	Arg	0.31
			48	Gln	-0.31
			60	Arg	-0.31
			77	Leu	-0.31
		A state of the sta	90	Pro	0
			100	Val	-0.45
			105	Leu	0
			114	Pro	-0.45
		1.4.			

 Table 9. (continued)

It is seen that Mycobacteriophage lysine B D29 has good docking scores with MarA (multidrug antibiotic resistant proteins), Erm37, whiB7. Patch dock server used to dock the proteins (Table 8). Protein protein model interaction analysed. Gromacs minimization energy by Galaxy Europe server and structural charges, aminoacids identification were performed using Vienna-ptm server.

Further docking is performed with the receptors in Table 6 with the Mycobacteriophage B lysine D29.

Dectin 1 receptor with WhiB7 bacterial proteins (Transciptional regulators) has good docking scores. It exhibit good binding sites.

To select the putative site, an analogous experiment was performed with the bacteriophage protein and the sites were compared. The lysine B bacteriophage D29 had close overlap with Mar A gene binding sites and the binding energies were comparable (delta G bind = -12638 kcal/mol). Final verification of docking experiments performed with MD simulation which suggested stable binding sites. To help understand discrimination

SL.NO	Human Receptors	Model	Numeral – residues	Amino -acids	Charges
1.	Complementary receptors		1 11	Val Thr	0.129 -0.31
	docked with Eis	A AM	20	Leu	-0.31
	protein.	and the second sec	30	Cys	0.31
	protein.		38	Ser	-0.31
			46	Pro	-0.31
			53	Thr	0.31
			62	Glu	0.31
		. (29)	72	Asp	0.31
			89	Trp	-0.31
			110	Pro	0.51
2.	Complementary		1	Gly	0.129
2.	protein docked		8	Leu	-0.31
	with InhA		26	Asp	-0.31
	protein	10 Mar 10	35	Gly	-0.31
	protein		40	Lys	-0.31
			53	Arg	-0.31
			70	Ile	-0.31
			80	Leu	-0.31
		130	88	Val	0.31
			104	Gly	-0.31
			120	Gly	0.01
3.	C-type lectin		1	Val	0.05
	domain family		11	Leu	-0.31
	7, member A	52 5 5 5	20	Ser	-0.31
	docked with		36	Pro	0
	RPOB		44	Cys	0.31
	-	2.	55	Pro	0.45
			65	Asn	0.31
			75	Trp	-0.31
			98	Ile	0
			115	Tyr	0.31
		r +Kest	135	Glu	0.16
4.	C-type lectin		1	Val	0.05
	domain family		11	Leu	-0.31
	7, member A	de la	20	Ser	-0.31
	docked with		36	Pro	0
	whiB7		45	Cys	0
			53	Pro	0
			65	Asn	-0.31
			75	Trp	-0.31
			96	Ile	-0.31
		The second	117	Trp	0
			133	Glu	-0.31

 Table 10. Simulation model of human receptors and bacterial protein.

(continued)

5.	C-X-C motif	1	1	Lys	0.05
	chemokine	a fallen .	16	Glu	-0.31
	ligand 8 docked		26	Leu	-0.31
	with Cytidine		36	Arg	0.31
	methyl		52	Cys	-0.31
	transferase(tlyA		60	Gln	0.31
)	ACTOR	65	Gln	-0.45
			75	Cys	0
		and the second	82	Ile	0
			94	Lys	0.05
			105	Thr	0.408
6.	IRAK4 docked		1	Arg	0.129
	with kasB	A starting	20	Phe	-0.31
			38	His	0.31
			52	Ser	-0.31
			60	Phe	0.31
		19 A	77	Ser	0.31
		and the second sec	88	Phe	0
			102	Tyr	0.31
		14 . · · ·	120	Glu	0.31
			130	Leu	
7.	C-X-C motif		1	Lys	0.05
	chemokine	and an a	16	Glu	-0.31
	ligand 8 docked	5-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	26	Leu	-0.31
	with Mutidrug		36	Arg	0.31
	antibiotic		52	Cys	-0.31
	resistant protein		60	Gln	0.31
	_		65	Gln	-0.45
			75	Cys	0
		3-63-6 T + C = 4	82	Ile	0
		• •	94	Lys	0.05
			105	Thr	0.408
8.	IRAK4 docked		1	Arg	0.129
	with expression		20	Phe	-0.31
	resistant	And	38	His	0.31
	macroloide(erm		52	Ser	0.31
	37)		60	Phe	0.31
			78	Ser	0
			88	Phe	0
			103	Tyr	0
			120	Glu	0.31
			130	Leu	0.31
		Millinge .	138	Lys	-0.31

 Table 10. (continued)

of different proteins in site 2, the docking of both protein protein was performed with a high precision Vienna-ptm server.

Molecular dynamics simulation of antibiotic resistant bacterial protein is selected sites for binding Mycobacteriophage lysine B D29 gp12 protein. MD simulation was performed in 150mM water at 300k for 100 ns (Table 9).

2 35 101111111111111111111111111111111111	471-01 19 9.406 3.930 4003 471-01 19 9.401 3.903 4.900 4.804 471-01 2.01 3.003 3.903 4.900 4.804 471-01 2.01 3.903 4.900 4.804 4.914 5.914
NLCU N 310 701 4 134 6430 SLCU 1 4 301 6054 4830 SLCU 1 4 301 6054 4830 SLCU 1 4 301 6054 4830 SLCU 1 4 301 6759 4 3464 6437 SLCU 1 4 301 6759 4 3464 6437 SLCU 1 4 301 6759 4 3464 6437 SLCU 1 4 301 6054 4830 5714 SLCU 1 4 301 6054 415 571 SLCU 1 4 301 6074 4417 571 SLCU 1 4 10077 4407 5101 SLCU 1 612 41 101304 4320 5.150 SLCU 1 612 41 10134 4320 4320 SLCU 1 612 41 0134 4320 4	Norma Carl, Carl, Sing, S
BMIND CA 75: 07.40.4 01.01 BMIND CA 75: 07.40.4 01.01 BMIND CA 75: 07.01	1 electronic 4 electronic 5 and 5 an
011113 12002 0114	100440 C 11001 110045 1005 107 100440 C 11001 11004 5074 504 110425 N 1600 11404 5074 504 110425 N 1600 11404 5074 506 110425 N 1600 1161 4077 4 56 110425 N 1601 1104 5074 402 110425 N 1601 1105 N 1604 402 110425 N 1601 1105 N 1604 402 110425 N 1601 1105 N 1604 402 11045 N 1601 N
TIGARD C 11/01 1/02/0 TIGARD C 11/01 1/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/02/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C 11/04/0 TIGARD C	1110AL CA 149/111115/504/509 1150AL CB 149/11113/504/503/578 1150AL CB 149/11121/505/5149 1150AL HCB 149/1123/505/5149 1150AL HCB 1169/1123/505/5149 1150AL HCB 1169/1123/505/5149 1150AL HCB 1169/1123/505/5149 1150AL HCB 1169/1123/505/5149 1150AL HCB 109/11113/505/5149 1150AL HCB 109/11113/505/504 1150AL HCB 1109/11113/505/504 1150AL HCB 1109/11113/505/504 1150AL HCB 1109/51113/505/504 1150AL HCB 1109/51113/505/504 1150AL HCB 1109/5113/505/504 1150AL HCB 1109/5113/505/504 1150AL HCB 1109/515/504 1150AL HCB 1109/5159/515/604 1150AL HCB 1109/5159/515/647 1150AL HCB 1109/5159/559/556/57 1150AL HCB 1109/519/515/647 1150AL HCB 1109/519/517/517 1150AL HCB 1109/
I SAAA, WHE 1954 LOADER 4,521,6327 I SAAA, WHE 1954 LOADER 4,521,6327 I SAAA, D 1936 TEBD 7,0809 ASH I STHIN 1,921 TO 101 A 7,000 ASH I STHIN 1,921 TO 101 A 7,000 ASH I STHIN A, 1939 TO 7,010 A 7,000 ASH I STHIN A, 1939 TO 7,010 A 7,000 ASH I STHIN A, 1939 TO 7,010 A 7,000 ASH I STHIN A, 1930 TO 7,000 A 201 I STHIN CO 1044 TO 7,000 A 201 I STHIN TO 7,000 A 201	1 39 40 A4011 1077 A029 4 00 A034 1374 1075 1077 A029 4 00 A035 1374 1075 11979 2008 2 707 4 00 A 25 1374 1075 11979 2008 2 707 4 00 A21 1374 1075 1076 1080 2 016 2 707 4 00 1374 1010 0 504 2 725 4 00 1374 1010 1010 554 2 725 4 00 1374 1010 1010 554 2 725 4 00 1384 101 100 100 7 40 0 740 0 40 1384 101 100 100 7 40 0 740 0 40 1384 101 100 100 7 40 0 740 0 40 1384 101 100 100 7 40 0 40 1384 101 100 100 7 40 0 740 0 40 1384 101 100 100 7 40 0 740 100 1384 101 100 100 7 40 7 202 1384 101 101 100 100 7 707 2 202
139GLU GE2 2013 0.081 7.752 0.594 139GLU GE2 2013 0.081 7.752 0.594 139GLU G 2015 9.52 7.756 6.789 14GLEU H 2017 9.51 7.956 6.725 14GLEU H 2017 9.51 7.956 6.725 14GLEU H 2017 9.51 7.956 6.725 14GLEU G 2019 9.548 1.966 6.70 14GLEU G 2019 9.548 1.966 6.70 14GLEU G 2019 9.548 0.964 14GLEU G 2019 9.548 0.964 14GLEU C 2019 9.548 0.964 14GLEU C 2019 9.548 0.964 14GLEU C 2019 9.548 0.964 14GLEU C 2019 9.987 8.925 6.794 14GLEU C 2019 9.997 8.925 6.794 14GLEU C 2019 9.997 8.925 6.794 14GLEU H 202 2019 9.978 8.956 7.194 14GLEU H 202 2019 9.978 8.971 1.396 14GLEU H 202 2019 9.978 8.971 1.3	2089/YCI HID 2003 7.069 7.8134 4.568 2089/YCI HID 2003 7.069 7.8134 4.568 2089/YCI HID 2019 7.727 4.563 4.518 2089/YCI HID 2009 7.727 7.914 4.568 2089/YCI HID 2009 7.727 7.914 4.868 2089/YCI HID 2019 7.727 7.914 4.861 2089/YCI HID 2017 7.708 4.268 2089/YCI HID 2715 7.708 4.865 2089/YCI HID 2715 7.708 4.865 2089/YCI HID 2715 7.708 4.865 2089/YCI HID 2715 7.708 4.865 2089/YCI HID 2715 7.208 4.865 2089/YCI HID 2715 7.208 4.865 2089/YCI HID 2715 7.208 5.861 2089/YCI HID 2715 7.208 5.861

Fig. 7. Gromacs energy minimization by using galaxy Europe

As per docking results and verification by molecular dynamics simulation it was found that the whib7 protein has good affinity in binding with Mycobacteriophage D29 lysin B. It depicts that Mycobacteriophage D29 Lysin B plays an important role at transcription process, it stop the transcription process of whib7 and do not allow the production of antibiotic resistant protein. Here we also characterize insilico the predicted interaction of gene protein 12 from Mycobacteriophage D29 with Mycobacterium tuberculosis antibiotic resistant protein (TlyA), Multidrug resistant protein(Mar A), Rifampin resistant protein(rpob), expression resistant macrolide (Erm 37). All these proteins plays an important role in the transcription process in bacterial cells and has been proposed (Table 10, Fig. 7).

4 Conclusion

The taxonomy and functional information of Mycobacterium tuberculosis microbiome are identified. As per docking studies and molecular dynamics simulation analysis it is seen that Mycobacteriophage lysin B D29 inhibits antibiotic resistant protein and hydrolysed mycolylarabinogalactan bonds. Further invitro or in vivo studies can be done on the Mycobacteriophage D29 lysin B to establish potential treatment against multi drug resistant strains i.e., *Mycobacterium tuberculosis*. Taxonomic profiling obtained using krona pie chart and Graphlan which depicts the existence of Multidrug resistance *Mycobacterium tuberculosis* sequence. The phylogenetic tree obtained from gene Superfamily tool which depicts the evolutionary relationship between Mycobacteriophage and multi drug *Mycobacterium Tuberculosis* strain. To analyse the action of Mycobacteriophage protein on Multidrug resistant *Mycobacterium Tuberculosis* proteins Homology modeling, docking studies was carried out. It was observed that Mycobacteriophage lysine B D29 was very active and showed inhibitory action of aminoacid on WHIB7 protein which was validated by using tool Molecular dynamic Simulation.

References

- 1. Mostafa, M. M., Nassef, M., & Badr, A. (2016). Computational determination of the effects of virulent Escherichia coli and salmonella bacteriophages on human gut. *Computer methods and programs in biomedicine*, *135*, 27-35.
- Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015). Revisiting phage therapy: new applications for old resources. *Trends in microbiology*, 23(4), 185-191.
- Reindel R, Fiore CR, (2017) Phage Therapy: Considerations and Challenges for Development, Clinical Infectious Diseases, Volume 64(11): 1589-1590
- 4. Wittebole, X., De Roock, S., & Opal, S. M. (2014). A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence*, *5*(1), 226-235.
- Leite, D. M. C., Brochet, X., Resch, G., Que, Y. A., Neves, A., & Peña-Reyes, C. (2018). Computational prediction of inter-species relationships through omics data analysis and machine learning. *BMC bioinformatics*, 19(14), 151-159.
- Fernández-Ruiz, I., Coutinho, F. H., & Rodriguez-Valera, F. (2018). Thousands of novel endolysins discovered in uncultured phage genomes. *Frontiers in microbiology*, 9, 1033.

- Lenneman, B. R., Fernbach, J., Loessner, M. J., Lu, T. K., & Kilcher, S. (2021). Enhancing phage therapy through synthetic biology and genome engineering. *Current Opinion in Biotechnology*, 68, 151-159.
- Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L., Lepore, R., Schwede, T. (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46(W1), W296-W303.
- Duhovny D, Nussinov R, Wolfson HJ. Efficient Unbound Docking of Rigid Molecules. In Gusfield et al., Ed. Proceedings of the 2'nd Workshop on Algorithms in Bioinformatics(WABI) Rome, Italy, Lecture Notes in Computer Science 2452, pp. 185-200, Springer Verlag, 2002.
- Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. (2005) PatchDock and Symm-Dock: servers for rigid and symmetric docking. Nucl. Acids. Res. 33: W363-367.
- 11. Andrews, S. (n.d.). FastQC A Quality Control tool for High Throughput Sequence Data. Retrieved from http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
- 12. usegalaxy.eu
- Kopylova, E., Noé, L., & Touzet, H. (2012). SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics, 28(24), 3211–3217. https://doi.org/ 10.1093/bioinformatics/bts611
- Blankenberg, D., Gordon, A., Von Kuster, G., Coraor, N., Taylor, J., & and, A. N. (2010). Manipulation of FASTQ data with Galaxy. Bioinformatics, 26(14), 1783–1785. https://doi. org/10.1093/bioinformatics/btq281
- Truong, D. T., Franzosa, E. A., Tickle, T. L., Scholz, M., Weingart, G., Pasolli, E., ... Segata, N. (2015). MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature Methods, 12(10), 902–903.
- Ondov, B. D., Bergman, N. H., & Phillippy, A. M. (2011). Interactive metagenomic visualization in a Web browser. BMC Bioinformatics, 12(1). https://doi.org/10.1186/1471-2105-12-385
- Asnicar, F., Weingart, G., Tickle, T. L., Huttenhower, C., & Segata, N. (2015). Compact graphical representation of phylogenetic data and metadata with GraPhlAn. PeerJ, 3, e1029. https://doi.org/10.7717/peerj.1029
- Abubucker, S., Segata, N., Goll, J., Schubert, A. M., Izard, J., Cantarel, B. L., ... Huttenhower, C. (2012). Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome. PLoS Computational Biology, 8(6), e1002358. https://doi.org/10.1371/journal. pcbi.1002358

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

